• 

  Covaxin booster dose neutralises Omicron, as well as Delta variants, says Bharat Biotech

  India | January 12, 2022 18:26 IST

  Covaxin ( BBV152) booster, India's indigenous vaccine, has shown that it can neutralize both Omicron and Delta variants of SARS-CoV-2, jab maker Bharat Biotech informed on Wednesday.

• 

  Covid vaccination pace in children shows youth's sense of responsibility, says PM Modi

  India | January 12, 2022 16:29 IST

  Hailing the pace of vaccination of the 15-18 years age group, PM Narendra Modi said this showed the sense of responsibility of the youngsters, especially witnessed during the pandemic period.  

• 

  Covaxin booster dose trial shows 'long-term safety', claims Bharat Biotech

  India | January 08, 2022 22:41 IST

  The Covaxin booster dose trial was performed on subjects 6 months after they received the second dose of the vaccine.

• 

  Bharat Biotech says paracetamol, painkillers not required for teens after getting Covaxin jab

  India | January 05, 2022 22:08 IST

  Bharat Biotech in a Twitter post said that no paracetamol or painkillers are recommended after being vaccinated with Covaxin.

• 

  Post COVID vaccine side-effects on children: No paracetamol advised after COVAXIN

  Health | January 06, 2022 13:49 IST

  Hyderabad-based vaccine manufacturer Bharat Biotech, on Wednesday, said that no paracetamol or pain killers are recommended for children after being vaccinated with COVAXIN. The parents of children under the 15-18 age group were concerned about the post-vaccine side effects. In case you are one of those, here is everything you should know.

• 

  Molnupiravir, oral anti-Covid medicine, set for launch in India; to cost Rs 649 per strip

  India | January 05, 2022 16:39 IST

  DCGI has approved molnupiravir for the treatment of adult patients with Covid-19 who have high risk of progression of the disease including hospitalisation or death.

• 

  Bharat Biotech's nasal Covid booster dose gets DCGI approval for Phase III trial

  India | January 05, 2022 12:46 IST

  Bharat Biotech aims to conduct clinical trials on 5,000 subjects (50 per cent vaccinated with Covishield and 50 per cent vaccinated with Covaxin).  

• 

  Bharat Biotech's nasal vaccine for booster dose? Key meeting today

  India | January 04, 2022 15:00 IST

  According to reports, Bharat Biotech has proposed that its nasal vaccine can be used as booster dose for those who have already been inoculated with Covaxin or Covishield vaccines against coronavirus.

• 

  Breaking myth: Safer for child to build immunity by getting infected with COVID-19 than vaccination?

  Health | January 03, 2022 13:25 IST

  Is it better for children to get infected by COVID 19 and then build immunity against it rather than vaccination? Absolutely not. Many myths about the COVID vaccine and its effect on children have begun circulating on the Internet giving rise to more confusion than ever. Let's debunk such myths here!

• 

  India Recap 2021: From Vaccine Century to General Rawat's death - What all made headlines

  India | December 31, 2021 13:01 IST

  India Recap 2021: India's journey throughout the year was full of many ups and downs. Let's take a quick recap of events that made headlines in 2021.

• 

  India total vaccination: 143.83 cr vaccine doses administered till December 30, 2021

  India | December 30, 2021 10:45 IST

  The Centre has ramped up door-to-door vaccination in order to achieve the target of 100 per cent vaccination of the eligible population who are supposed to receive the jab.

Advertisement
• 

  Government issues guidelines for vaccination of children, 'precautionary' doses | Top points

  India | December 27, 2021 23:44 IST

  Citizens irrespective of their income status are entitled to free COVID-19 vaccination at Government Vaccination Centres.

• 

  Covid-19: For now, Covaxin likely to be only vaccine available for children of 15-18 yrs

  India | December 26, 2021 23:20 IST

  The healthcare and frontline workers and citizens above 60 years of age with comorbidities would be administered the third dose of the same vaccine they had been given before.

• 

  Expert panel gives nod to Bharat Biotech's Covaxin jab for kids aged 12 and above

  India | December 25, 2021 22:59 IST

  Covaxin is now the second vaccine cleared for use for children in India.

• 

  Over 60% of India's population fully vaccinated against Covid-19

  India | December 23, 2021 12:13 IST

  The cumulative doses administered in the country so far under the nationwide COVID-19 vaccination drive has exceeded 139.70 crore.

• 

  Will current vaccines remain effective against Omicron? Drugmakers explain

  India | December 02, 2021 16:52 IST

  With Omicron raising concerns about Covid vaccines' efficacy, drugmakers are stress-testing existing jabs while also racing to prepare new formulas.

• 

  Bharat Biotech to commence exports of Covaxin to additional countries from December

  India | November 29, 2021 16:04 IST

  Earlier last week, vaccine major Serum Institute of India had said that it has resumed exports of its vaccine Covishield to the international vaccine sharing program COVAX.

• 

  Experts allay Covaxin concerns, say 50 pc effectiveness against Delta-driven Covid surge not bad

  India | November 26, 2021 14:08 IST

  The results of the first real-world assessment of Covaxin published in The Lancet Infectious Diseases journal on Wednesday showed that two doses of the vaccine, also known as BBV152, are 50 per cent effective against the symptomatic disease.

• 

  Lancet Infectious Diseases study compare well with phase 3 COVAXIN clinical trials: Bharat Biotech

  India | November 25, 2021 12:33 IST

  2 doses of COVID vaccine Covaxin (BBV152) are 50 pc effective against symptomatic COVID disease, according to 1st real-world assessment of COVID vaccine published in the Lancet Infectious Diseases journal.

• 

  Covaxin shows 50% effectiveness against symptomatic COVID in real-world assessment: Lancet study

  India | November 24, 2021 8:56 IST

  Researchers noted that Delta variant was the dominant strain in India during the study period, accounting for approximately 80 pc of all confirmed COVID cases.